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Abstract
To pinpoint the exact location of the etiological variant/s present at 1q21.1 harboring FCRL1-5 and CD5L genes, we carried
out a refined association study in the entire FCRL region in 1,536 patients with Graves’ disease (GD) and 1,516 sex-matched
controls by imputation analysis, logistic regression, and cis-eQTL analysis. Among 516 SNPs with P,0.05 in the initial GWAS
scan, the strongest signals associated with GD and correlated to FCRL3 expression were located at a cluster of SNPs
including rs7528684 and rs3761959. And the allele-specific effects for rs3761959 and rs7528684 on FCRL3 expression level
revealed that the risk alleles A of rs3761959 and C of rs7528684 were correlated with the elevated expression level of FCRL3
whether in PBMCs or its subsets, especially in CD19
+ B cells and CD8
+ T subsets. Next, the combined analysis with 5,300 GD
cases and 4,916 control individuals confirmed FCRL3 was a susceptibility gene of GD in Chinese Han populations, and
rs3761959 and rs7528684 met the genome-wide association significance level (Pcombined=2.27610
212 and 7.11610
213,
respectively). Moreover, the haplotypes with the risk allele A of rs3761959 and risk allele C of rs7528684 were associated
with GD risk. Finally, our epigenetic analysis suggested the disease-associated C allele of rs7528684 increased affinity for NF-
KB transcription factor. Above data indicated that FCRL3 gene and its proxy SNP rs7528684 may be involved in the
pathogenesis of GD by excessive inhibiting B cell receptor signaling and the impairment of suppressing function of Tregs.
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Introduction
Graves’ disease (GD), the most frequent form of autoimmune
thyroid disease (AITD), is triggered by the combination of genetic
susceptibility and environmental encounters. Using the candidate
gene strategy, several susceptibility genes for GD have been
validated in different ethnic populations and have been divided
into two classes: one class is immune-related genes, such as HLA on
6p21 [1,2], CTLA-4 on 2q33 [3,4], CD40 on 20q12 [5,6], PTPN22
on 1p13 [7–9], as well as SCGB3A2 on 5q31 [10–12]; and the
other class is thyroid-specific gene, such as TSHR on 14q31
[13,14].
FC receptor-like-3 (FCRL3, also known as CD307c) on 1q21.1
encodes a member of the immunoglobulin receptor superfamily
and is one of several Fc receptor-like glycoproteins. The encoded
protein of FCRL3 contains immunoreceptor-tyrosine activation
motifs and immunoreceptor-tyrosine inhibitory motifs in its
cytoplasmic domain and may play a role in regulation of the
immune system. The 1p21–23 region, in which the FCRL family
resides, has been identified as a candidate locus for multiple
autoimmune disorders in both human and murine models [15].
Mutations in FCRL3 have been reported to be associated with a
plethora of autoimmune diseases, such as rheumatoid arthritis,
systemic lupus erythematosus, and AITD [16–18]. Recently, two
genome-wide association studies (GWAS) from Wellcome Trust
Case Control Consortium (WTCCC) and our group, both
identified FCRL3 as a susceptibility gene of GD in individuals of
European ancestry and Chinese Han populations, respectively
PLOS ONE | www.plosone.org 1 March 2013 | Volume 8 | Issue 3 | e57758[19,20]. After the WTCCC GWAS, a case–control association
study investigating twelve tag SNPs within FCRL5 was performed
in 2,504 UK Caucasian patients with GD and 2,688 geograph-
ically matched controls and the results suggested that the
association of FCRL5 with GD is secondary to the effect of FCRL3
[21]. Nevertheless, a refined association study in the entire FCRL
region is required to determine the exact location of the etiological
variant/s present.
In this study, we refined the association in the 1q21.1 region
harborbing FCRL1-5 and CD5L, and confirmed FCRL3 was a
susceptibility gene of GD in Chinese Han populations and the
most significant signals associated with GD and correlated to
FCRL3 expression were located at a cluster of SNPs including
rs3761959 and rs7528684. Moreover, the haplotypes with the risk
allele A of rs3761959 and the risk allele C of rs7528684 were
associated with the predisposition of GD and can up-regulate the
mRNA expression level of FCRL3, whether in peripheral blood
mononuclear cells (PBMCs) or the subsets of PBMCs, especially in
CD19
+ B cells and CD8
+ T subsets. Finally, the risk allele C of
rs7528684 can increase the binding with NF-KB transcription
factor, resulting in the pathogenesis of GD.
Materials and Methods
Subjects
All samples were recruited from Chinese Han population
through collaboration with multiple hospitals in China. This study
was approved by the local ethics committee from Ruijin Hospital,
the Central Hospital of Xuzhou, the first affiliated hospital of
Bengbu Medical College, Medical School Hospital of Qingdao
University, and Linyi People’s Hospital, respectively. And all
subjects in this study provided written informed consent using
protocols approved by local ethics committee. As mentioned in our
previous GWAS paper, 1,536 patients with GD and 1,516 sex-
matched controls were recruited for the initial GWAS stage, and
additional 3,994 patients with GD and 3,510 sex-matched controls
were recruited for the replication study [4,10,20]. Diagnosis of GD
was based on documented clinical and biochemical evidence of
hyperthyroidism, diffuse goiter, and the presence of at least one of
the following: positive TRAb tests, diffusely increased
131I uptake
in thyroid gland, or exophthalmos [4,10,20]. All individuals
classified as GD were interviewed and examined by experienced
clinicians.
All the 1,516 controls in the GWAS stage were individuals with
neither GD nor family history of GD, and without any other
autoimmune disorders. Control subjects were matched for sex with
cases and were over 35 years. Since GD or other AITD has a
preponderance in the young female population, this age criteria
could reduce the number of controls who might develop GD later
on. To exclude clinical or sub-clinical AITD, the levels of sensitive
TSH (sTSH) and TPOAb in control subjects were measured using
chemiluminescence immunoassay (CLIA) in our laboratory. Of
the 1,832 healthy controls whose levels of sensitive TSH and
TPOAb were measured, 257 individuals with the levels of TPOAb
$5.61 U/ml, and 94 subjects with the levels of sensitive TSH
$4.94 mU/ml or #0.35 mU/ml were excluded, the remaining
1,516 served as the control cohort in the GWAS stage [20].
Genotyping and Quality Control
GWAS was performed by Illumina Human660-Quad Bead-
Chips [20]. Genotype clustering was conducted using Illumina
GenomeStudio V2011.1 software based on the 660W-
Quad_v1_H manifest files. This software, which is used to convert
the fluorescence intensities into SNP genotypes, was different from
the software used in the previously published GWAS paper [20].
The mean call rate across all samples was 99.8%. Quality filtering
was performed on SNPs and samples before analysis to ensure
robust association tests. Cryptic relationships between genotyped
individuals were examined using pairwise identity-by-descent
(IBD) estimation by PLINK software [20]. To maintain the
maximum number of available samples, all the pairwise relation-
ships were evaluated and the person who formed the node that
related to the most other nodes in the family trees was first
excluded. This process was iterated several times until the
remaining samples were not related to one another.
Of the 655,214 markers assayed, 3,185 that were from the Y or
mitochondrial chromosomes or were CNV-related were excluded.
Next, 168,082 markers with Hardy-Weinberg equilibrium
P#10
26, with genotype call rates below 98%, or with a minor
allele frequency (MAF) ,0.01 were discarded, leaving 483,947
SNPs for subsequent analysis. After removing samples with low
call rates (,98%, n=23), gender inconsistencies (n=6), and
cryptic relatedness (n=113), 2,910 samples were available for
further association analysis.
In the replication cohort, six SNPs on 1q21.1 were genotyped
using TaqMan SNP Genotyping Assays in Fludigm EP1 platform
[20], and one SNP (rs7528684) was genotyped using ABI 7900HT
platform. Of the seven SNPs genotyped, none of SNPs was
removed for further association analysis. Ultimately, 3,655 GD
patients and 3,385 controls with a 100% call rate were analyzed in
the replication cohorts.
Statistical Analysis
After quality control [20], we used the genotypes of 67 SNPs on
1q21.1 in 1,442 patients with GD and 1,468 controls for
association analysis using the Cochran-Armitage trend test by
PLINK [22]. The forward and two locus logistic regression
analysis were performed using R statistics packages. The linkage
disequilibrium (LD) block was analyzed by Haploview software
version 4.2.
The genotype imputation was performed using IMPUTE2
software [23] and the updated 1000G phase 1 integrated variant
set (Mar 2012) were used as a reference. Of the imputed SNPs, we
analyzed only those that could be imputed with a relatively high
confidence (estimated probability .0.9), had a MAF .1%, a
genotype call rate .98%, and a Hardy-Weinberg equilibrium P-
value .10
26. To take into account the uncertainty of imputed
SNPs, the association analysis of the imputed SNPs was carried out
utilizing the SNPTEST v2 software [24].
We inspected three eQTL databases from European Caucasian
population. One was developed by Dixon et al. and contained 405
children of British descent organized into 206 sibships including
297 sib pairs and 11 half-sib pairs [25]. Another database assessed
the transcriptome of circulating monocytes from 1,490 German
individuals [26]. The third database was the cell type–specific
eQTLs relevant to immunity and inflammation in paired samples
of primary monocytes and B cells, purified by positive selection
directly from 283 healthy British individuals [27].
For the replication stage, the Cochran-Armitage test for trend
was used to examine the associations. Association analysis in the
combined samples was performed by Cochran-Mantel-Hanezel
stratification analysis [22]. We examined heterogeneity among
studies using the Breslow-Day test [22,28]. The genome-wide
significance level was set at 5610
28, in keeping with the current
consensus of the field.
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PLOS ONE | www.plosone.org 2 March 2013 | Volume 8 | Issue 3 | e57758Figure 1. Regional plots of association results, logistic regression analysis, and cis-eQTL analysis at 1q21.1 and expression analysis
of FCRL3. Panel A shows the GD association of 67 genotyped and 972 imputed SNPs in the GWAS samples. The color of each genotyped SNP spot
reflects its r
2 with the top SNP within each association locus shown as a large red diamond, and smaller values changing from red to white. Genetic
recombination rates are shown in cyan. Genetic recombination rates, estimated using the 1000 Genomes pilot 1 CHB and JPT samples, are showing
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Blood samples (10 ml) were collected from 95 unrelated healthy
Chinese Han volunteers for gene expression analysis in PBMCs.
Samples with more blood volume (100 ml) were donated by these
95 individuals for gene expression assay in distinct subpopulations
of PBMCs. The genotypes of rs761959 and rs7528684 among
these 95 individuals were determined using the ABI 7900HT
System (AA and TT, n=29; AG and TC, n=47; and GG and
CC, n=19). The CD4
+, CD8
+, CD14
+ and CD19
+ subsets of
PBMCs were isolated using MACS Column kits (Miltenyi Biotec)
according to the manufacturer’s instructions. The purity of each
cell subpopulation was determined by an LSR II Flow Cytometer
(BD Biosciences), and the cell subpopulations with the purity of
over 90% were used for real time RT-PCR [20]. The mean
purities of the CD4
+, CD8
+, CD14
+ and CD19
+ subsets were
98.361.7%, 98.361.7%, 96.961.9% and 96.262.5%, respec-
tively [20]. cDNAs were made from 1 mg RNA templates using
reverse transcriptase and oligo(dT) primer (Promega). Quantitative
RT-PCRs for FCRL3 at 1q21.1 were performed in duplicate using
the SYBR Green and an ABI 7900HT Fast Real-Time PCR
System. Expression of all samples was normalized to the relative
expression level of GAPDH. Primer sequences for real-time PCR
were as follows: human FCRL3 primers (forward, 59 TGGAGA-
TAGCAACCCGATTTATTC 39; reverse, 59
CTGTAAGTTCCTCATGCTCTTGATG 39) and GAPDH (for-
ward, 59 GAAGGTGAAGGTCGGAGTC 39; reverse, 59 GAA-
GATGGTGATGGGATTTC 39). We performed statistical anal-
ysis for expression data using ANOVA and an unpaired Student’s
t-test (the two tail P value is indicated on the figures).
Results
The association and cis-gene expression (cis-eQTL) analysis in
the initial GWAS scan cohort.
Our previous two-staged GWAS illustrated that FCRL3 was a
predisposing gene of GD on 1q21.1 harboring FCRL1-5 and CD5L
genes [20]. To pinpoint the exact location of the etiological
variant/s present, we carried out the imputation analysis in the
initial scan cohorts with 1,442 affected individuals and 1,468
controls. Within the ,414-kb region of high LD at 1q21.1, there
were 67 genotyped SNPs and 972 imputed SNPs (Figure 1A,
Table S1). The mean variant density was 2.5 SNPs per 1-kb and
can well tag all currently known common variation within this
region. Among the 1,039 SNPs, there were 516 SNPs with P,0.05
and 124 SNPs with P,0.0001, respectively (Figure 1A, Table S1).
Remarkably, the P levels of 44 SNPs located in FCRL3-CD5L gene
region were less than 1.00610
27 in the initial scan cohorts
(Figure 1A, Table S1, and Figure S1A).
To investigate the independent variant associated with GD on
1q21.1, we carried out the forward logistic regression analysis for
the 124 SNPs with P,0.0001 using R statistics packages and the
results displayed that rs3761959 was an independent variant in the
original scan cohort. Next, the two locus logistic regression analysis
was performed to confirm the independent variant. As shown in
Figure 1B, rs3761959 selected as the best SNP on 1q21.1, was put
individually into the regression models, and all other markers were
sequentially added to see if a second locus could improve the
model. The two locus logistic regression results in the original scan
manifested that none of 1,031 SNPs (except 7 SNPs with high LD
with rs3761959, r
2$0.99, Figure S1A) improved the model with
rs3761959 at the P,0.001 level (Figure 1B). Conversely, the
majority of SNPs, except for 50 SNPs with significant P value with
the GD risk (P,2.30610
26; Figure S1B) and within a high LD
region (r
2.0.70; Figure S1A), were improved by adding
rs3761959 (Figure 1B). The logistic regression analysis could not
pinpoint which SNP was the independent variant among a cluster
of SNPs in a high LD block.
To further determine the most significant variant correlated
with the FCRL1-5 expression within 1q21.1 region, we carried out
the cis-eQTL analysis for the 516 SNPs with P,0.05 in the
GWAS scan cohort (Figure 1A, Table S1). From the cis-eQTL
analysis using transcriptome data from about 400 lymphoblastoid
cell lines [25], we found that the expression level of FCRL3 was
associated with a cluster of SNPs, with the strongest signal at
rs7528684 (P=3.38610
211 for probeset 231093_at; Figure 1C).
Other three SNPs (rs2210913, rs3761959, and rs945635), which
were all in high LD with rs7528684 (r
2=1 in our data, Figure
S1A), also exhibited the significant correlation with FCRL3
expression (P,1.00610
210 for probeset 231093_at; Figure 1C).
Furthermore, the four SNPs also showed the eQTL effect on the
expression of FCRL5 (P,5.77610
28 for probeset 224405_at;
Figure 1C). Nonetheless, among a cluster of SNPs with the
association with FCRL5 expression, the strongest signal was
located at rs6679793 (P=5.90610
218 for probeset 224405_at;
Figure 1C), which was not in high LD with any SNP associated
with the FCRL3 expression and was weakly associated with GD in
the original GWAS scan, in FCRL5 (r
2,0.12, PGWAS=0. 0252;
Figure 1A, Figure S2, and Table S1).
Additionally, we inspected a cis-eQTL database assessing the
transcriptome of circulating monocytes from 1,490 individuals
[26] and found rs7528684 was correlated with FCRL3 expression
level (P=1.41610
28; Figure 1D). Also, two SNPs (rs6681271 and
rs7522061), which were in high LD with rs7528684 and
rs3761959 (r
2=0.99, Figure S1A), displayed the high correlation
with FCRL3 (P=1.89610
28 and 1.65610
28; Figure 1D).
cyan. Physical positions are based on NCBI build 36. Panel B shows the two locus logistic regression analysis results for 1,039 SNPs at 1q21.1 in the
GWAS samples. The SNPs were improved by adding rs3761959 were shown in red points; whileas, the SNPs improved the model with rs3761959 were
showed in blue triangles. Panels C,D,E, and F show the cis-eQTL analysis of 516 SNPs with P,0.05 in the initial GWAS scan from three different cis-
eQTL databases. Panel C shows plot of linkage disequilibrium (LD) structures at 1q21.1 and correlation of SNPs to transcript abundances of FCRL3 and
FCRL5 genes at 1q21.1 in transcriptome data from about 400 lymphoblastoid cell lines. The LD structures of 1,039 SNPs at 1q21.1 were analyzed by
Haploview software version 4.2 based on our imputed data. The LD color scheme is stratified according to the logarithm of the odds (LOD) score and
D9: LOD ,2 (white for D9, 1 and blue for D9=1) or LOD .2 (shades of pink/red for D9, 1 and bright red for D9=1). Two different red crosses
indicate the association results of SNPs to the expression level of FCRL3. Three different blue signs indicate the correlation results of SNPs to the
expression level of FCRL5. Panel D shows the correlation of 10 SNPs to transcript abundances of FCRL3 in the transcriptome of circulating monocytes
from 1,490 individuals. Panel E shows the correlation of SNPs to the expression of FCRL3 in both-cis dataset of the cell type–specific cis-eQTL
database. The expression levels of FCRL3 in B cell and monocyte were shown in red and blue color, respectively. FCRL3 expression detected by
different probe was shown in two different crosses. Panel F shows the correlation of SNPs to the expression of FCRL3 and FCRL5 in B-cis dataset of the
cell type–specific cis-eQTL database. The expression of FCRL3 was shown in different red signs and that of FCRL5 was shown in blue. Panel G shows
the relative mRNA expression levels of FCRL3 for different genotypes of rs3761959 and rs7528684 in PBMCs from 95 individuals (GG and TT, n=29; GA
and TC, n=47; and AA and CC, n=19). Panel H shows the relative mRNA expression levels of FCRL3 for different genotypes of rs3761959 and
rs7528684 in the subset of PBMCs from above 95 individuals. *, P,0.05; **, P,0.01; ***, P,0.001.
doi:10.1371/journal.pone.0057758.g001
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PLOS ONE | www.plosone.org 5 March 2013 | Volume 8 | Issue 3 | e57758Ultimately, we also inspected a cell type–specific cis-eQTL
database relevant to immunity and inflammation in purified B-cell
and monocyte populations [27]. Of note, in the both-cis dataset,
among a cluster of SNPs correlated with the expression of FCRL3,
rs7528684 displayed higher correlation in the B cell
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Figure 2. Regional plots of association results and logistic
regression analysis in the combined population at 1q21.1.
Panel A shows the linkage disequilibrium block analysis for the 12 SNPs
with PGWAS ,0.0001, which can be tagged by seven replicated SNPs in
the combined population by using haploview software 4.2. Panel B
shows the GD association of seven replicated SNPs in the combined
population. The color of each genotyped SNP spot reflects its r
2 with
the top SNP within each association locus shown as a large red
diamond, and smaller values changing from red to white. Genetic
recombination rates are shown in cyan. Genetic recombination rates,
estimated using the 1000 Genomes pilot 1 CHB and JPT samples, are
showing cyan. Physical positions are based on NCBI build 36. Panel C
shows the two locus logistic regression results for seven SNPs at 1q21.1
in the combined population. The SNPs were improved by adding
rs7528684 were shown in red points; whileas, the SNPs improved the
model with rs7528684 were showed in blue triangles.
doi:10.1371/journal.pone.0057758.g002
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233 for nuID KV7kDSLO4uggquLXB4 and
P=5.93610
226 for nuID 67unrLpPnjv_uzOezU; Figure 1E) than
that in the mono-cell (P=2.35610
26 for nuID KV7kDSLO4ugg-
quLXB4 and P=0.0001 for nuID 67unrLpPnjv_uzOezU;
Figure 1E). In the B cell-cis dataset, rs7528684 also manifested
the highest correlation with FCRL3 expression (P=2.37610
230 for
nuID ZUclXxUi6VEoBJeRT8; Figure 1F).
To confirmed the cis-eQTL analysis, We then evaluated allele-
specific effects for rs3761959 and rs7528684 on the mRNA
expression of FCRL3 gene in PBMCs from 95 individuals and the
result revealed both genotypes were correlated with the expression
levels of FCRL3 (PANOVA=0.0009) (Figure 1G). We then detected
the expression of FCRL3 in distinct PBMC populations. Although
FCRL3 was expressed in all subsets of PBMCs, there were higher
expression levels of FCRL3 in CD19
+ B cells and CD8
+ T subsets
than those in CD4
+ T subsets and CD14
+ monocytes (Figure 1H).
More specifically, both risk alleles A of rs3761959 and C of
rs7528684 can significantly up-regulate the mRNA level of FCRL3
in all subsets of PBMCs, especially in CD19
+ B cells and CD8
+ T
subsets isolated from 95 healthy volunteers (PANOVA: 0.0001 in
CD4
+ T subsets, 1.72610
25 in CD8
+ T subsets, 0.0122 in CD14
+
monocytes, and 9.85610
27 in CD19
+ B cells, respectively;
Figure 1H).
The Association Analysis in the Replication and
Combined Cohort
Among the 124 SNPs with P,0.0001 in FCRL3-CD5L gene
region, 11 SNPs were genotyped and 113 SNPs were imputed in
the initial scan (Figure 1A, Table S1, and Figure S1A). Next, six
genotyped SNPs tagging 11 genotyped SNPs with P,0.0001 and
one imputed SNP (rs7528684), which were all related to FCRL3
expression, were genotyped in the second cohort (Figure 2A). After
quality control, the most significant association signal was
observed at rs7528684 in 3,655 patients with GD and 3,385
controls (allele frequencies Preplication=5.44610
27, OR=1.19,
95%CI=1.11–1.27; and genotype distributions Preplica-
tion=3.40610
26, TC: OR=1.17, 95%CI=1.06–1.30, CC:
OR=1.42, 95%CI=1.23–1.63; Table 1). Concordantly, among
the seven SNPs genotyped for replication, rs7528684 displayed the
highest significance in the combined datasets with 5,107 GD cases
and 4,853 control individuals (allele frequencies Pcom-
bined=7.11610
213, OR=1.23, 95%CI=1.16–1.30; and geno-
type distributions Pcombined=4.87610
212, TC: OR=1.20,
95%CI=1.09–1.31, CC: OR=1.53, 95%CI=1.36–1.71;
Table 1; Figure 2B). Meanwhile, rs3761959 also met the
genome-wide association level in the combined cohort (allele
frequencies Pcombined=2.27610
212, OR=1.22, 95%CI=1.16–
1.30; and genotype distributions Pcombined=1.60610
212, GA:
OR=1.19, 95%CI=1.09–1.30, AA: OR=1.51, 95%CI=1.35–
1.70; Table 1; Figure 2B). In addition, the forward and two-locus
logistic regression analysis in the combined population demon-
Table 2. Frequencies of the haplotypes on 1q23.1 in the combined population.
rs10908583 rs2210911 rs3761959 rs7528684 rs7517644 rs2765493 rs2260040 control N(%) case N(%) P OR (95% CI)
T G A C G G G 1199 (12.4) 1476 (14.5) 1.15610
25 1.20 (1.11–1.30)
T G A C A G A 1230 (12.7) 1405 (13.8) 0.0214 1.10 (1.01–1.20)
T G A C A A A 543 (5.6) 669 (6.6) 0.0044 1.18 (1.05–1.33)
T A A C A G A 562 (5.8) 633 (6.2) 0.2154 1.08 (0.96–1.21)
C A G T A G A 454 (4.7) 468 (4.6) 0.7677 0.98 (0.86–1.12)
T G G T A A A 534 (5.5) 490 (4.8) 0.0262 0.87 (0.76–0.98)
C A G T A A A 4668 (48.2) 4511 (44.3) 4.73610
28 0.86 (0.81–0.91)
Bold letters indicate those haplotypes with significant differences between GD and normal subjects. All data shown here are haplotypes whose frequencies are more
than 2%.
doi:10.1371/journal.pone.0057758.t002
Figure 3. The epigenetic analysis from the ENCODE database. The chromosome region containing rs7528684 displayed no DNaseI
hypersensitivity and can bind the transcription factor. However, the region harboring rs3761959 shows no binding with the transcription factor.
doi:10.1371/journal.pone.0057758.g003
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rs3761959 and rs3761959 also could not improve the model with
rs7528684 (Figure 2C).
Because multiple SNPs may act in combination to increase the
risk of disease, haplotypes of the SNPs in the combined population
were investigated and their frequencies in the GD and control
groups were compared. The results displayed that seven haplo-
types with a frequency of more than 4% were formed from seven
SNPs and accounted for about 95% of all haplotypes (Table 2).
Four of seven haplotypes exhibited significantly higher frequencies
among individuals with GD than the control group. As shown in
Table 2, the haplotype TGACGGG manifested the highest
statistical difference (P=1.15610
25, OR=1.20, 95%CI=1.11–
1.30; Table 2), followed by haplotypes TGACAGA and
TGACAAA (P=0.0214, OR=1.10, 95%CI=1.01–1.20; and
P=0.0044, OR=1.18, 95%CI=1.05–1.33, respectively;
Table 2). In contrast, haplotypes CAGTAAA and TGGTAAA
were more frequently observed in controls than in patients with
GD (P=4.73610
28, OR=0.86, 95%CI=0.81–0.91; and P=0.
0262, OR=0.87, 95%CI=0.76–0.98, respectively; Table 2).
Notably, all the risk haplotypes of GD contained the risk allele
A of rs3761959 and risk allele C of rs7528684 and all the protected
haplotypes of GD contained the protected allele G of rs3761959
and protected allele T of rs7528684 (Table 2).
Ultimately, we used the ENCODE databases of epigenetic study
to narrow down the candidate regulatory regions and polymor-
phisms (http://genome.ucsc.edu/ENCODE/) [29]. The data
from ENCODE manifested the chromosome region containing
rs7528684 was without a DNaseI hypersensitivity, however, can
bind the transcription factor (Figure 3). Also, we found the risk
allele C of rs7528684 can bind the transcription factor NF-KB
utilizing the Searching Transcription Factor Binding Sites
(TFSEARCH, ver 1.3) (score: 96.9) [30]. The previous study also
found rs7528684 could affect the FCRL3 expression in the
luciferase assay [16]. Whereas, the chromosome region containing
rs3761959 could not bind the transcription factors (Figure 3),
suggesting the association between rs3761959 and GD because of
its high LD with rs7528684.
The false positive report probability (FPRP) of the SNPs with
significant association to GD in the combined Chinese Han cohort
was also analyzed. In the present study, the FPRP value was
calculated for each genetic variant using the assigned prior
probability range, the statistical power to detect an odds ratio of
1.5, and detected odds ratios and P values. As shown in Table 3,
among the seven genetic variants, the FPRP values of five SNPs
were below 0.2 for the prior probability from 0.25 to 0.00001,
which was a relatively high prior probability range. In addition,
the FPRP values for rs7528684 were still the lowest even for a
prior probability of 0.00001 (Table 3). Interestingly, the case-
control association study for these seven SNPs with significant
differences in allele frequencies between the 5,107 patients with
GD and 4,853 control individuals has 100% statistical power to
detect a SNP with an a level equal to their reported P value,
corresponding to relative risks of 1.5 for GD (Table 3).
Discussion
Our refined association study of the SNPs on 1q21.1 region
verified that FCRL3 was the susceptibility gene for GD in the
Chinese Han population. Moreover, the logistic regression analysis
revealed that 8 SNPs including rs3761959 may be the most likely
susceptibility variant. Cis-eQTL analysis from three databases
indicated that the most significant signals correlated to the
expression of FCRL3 were located at a cluster of SNPs including
rs3761959 and rs7528684. In the combined population analysis,
the risk haplotypes containing the risk allele A of rs3761959 and
risk allele C of rs7528684 were associated with the predisposition
of GD. Furthermore, the risk allele A of rs3761959 and risk allele
C of rs7528684 increased FCRL3 expression whether in PBMCs or
in its subsets, especially in CD19
+ B cells and CD8
+ T subsets.
However, only rs7528684 can bind the NF-KB transcription
factor to affect the FCRL3 expression. Intriguingly, the FPRP value
for SNP rs7528684 was very low for the prior probability range
and was quite robust even for low prior probabilities. These results
suggested that rs7528684 in the promoter of FCRL3 was associated
with GD etiology in the combined Chinese Han population.
The first reported variant about the association of FCRL3 with
GD was rs7528684 located at position –169 in promoter of FCRL3
gene in a Japanese population (P=7.4610
25) [16], which was
confirmed by the later study in 1,056 UK patients with GD and
864 controls (P=0.024) [31]. Our two-stage GWAS analysis also
confirmed rs7528684 was associated with GD in Chinese Han
population. Although there were two negative conclusions
regarding association of rs7528684 in FCRL3 with GD in two
small samples studies: one was in a Chinese population with 436
cases and 316 controls [32], and the other was in a UK population
Table 3. False positive report probability (FPRP) values for seven SNPs with significant difference between 5,300 patients with GD
and 4,916 health individuals.
SNP
Odds ratio (95%
CI)
Reported
p-Value
Statistical power
under recessive
model
a Prior probability
0.25 0.1 0.01 0.001 0.0001 0.00001
rs10908583 1.16 (1.10–1.23) 8.55610
28 1.0000 2.59610
27 7.77610
27 8.54610
26 8.62610
25 0.0009 0.0086
rs2210911 1.16 (1.09–1.23) 4.98610
27 1.0000 1.32610
26 3.95610
26 4.35610
25 0.0004 0.0044 0.0420
rs3761959 1.22 (1.16–1.30) 2.27610
212 1.0000 6.07610
212 1.82610
211 2.00610
210 2.02610
29 2.02610
28 2.02610
27
rs7528684 1.23 (1.16–1.30) 7.11610
213 1.0000 1.83610
212 5.48610
212 6.03610
211 6.08610
210 6.09610
29 6.09610
28
rs7517644 1.19 (1.10–1.28) 1.70610
25 1.0000 4.96610
25 0.0001 0.0016 0.0162 0.1418 0.6230
rs2765493 1.16 (1.10–1.23) 2.16610
27 1.0000 5.69610
27 1.71610
26 1.88610
25 0.0002 0.0019 0.0186
rs2260040 1.15 (1.07–1.24) 0.0003 1.0000 0.0009 0.0026 0.0275 0.2218 0.7405 0.9661
aStatistical power is the power to detect an odds ratio of 1.5 for the homozygotes with the rare genetic variant, with an a level equal to the reported p-Value. FPRP
values below 0.2 are in bold face.
doi:10.1371/journal.pone.0057758.t003
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regarded SNP rs7528684 as a susceptibility GD locus in FCRL3
region in the Chinese Han population. Meanwhile, all of the risk
haplotypes of GD contained the risk allele C of rs7528684, which
can increase FCRL3 expression both from cis-eQTL analysis and
from the real-time PCR results.
Later, WTCCC in an analysis including 2,500 UK GD cases
and 2,500 controls found an association at rs3761959 (a perfect
proxy of rs7528684, r
2=1 in our data; Figure 2A) with GD
(P=0.0094; Table S2) [19]. Also, rs3761959 showed the
significant association with GD in our two-stage GWAS analysis
and could affect the expression of FCRL3 from our cis-eQTL
analysis and real-time PCR. Noteworthy, in the WTCCC study, a
stronger association was found with rs11264798 (in high LD with
rs7528684 in our data, r
2=0.99, P=1.6610
25; Table S2), located
in the intron 8 of FCRL3 [19]. More recently, the WTCCC
genotyped 743 SNPs across FCRL3 in 7,894 control samples and
about 2,000 GD subjects to define the causal GD-associated SNPs
using Bayes theorem [34]. Unfortunately, the fine mapping data
from WTCCC failed to refine the signal in FCRL3 due to the 95%
credible set containing 114 SNPs, albeit the top SNP, rs11264798,
accounting for 7% of the posterior weight (Table S2) [34]. The
imputation analysis manifested that SNP rs11264798 was also
associated with GD in our initial scan cohort (PGWAS=4.29610
27;
Table S2). At the same time, we compared our data with those in
the study by Simmonds et al that also fine-mapped the FCRL5
region in a UK population and found none of 11 SNPs (excluding
SNP rs3900700 because of MAF ,0.01 in Chinese Han
population) showed the association with GD in the Chinese Han
population at the P,0.05 level (Table S2). Above results suggests
that rs7528684 should be the likely FCRL etiological variant in our
Chinese Han GD population, albeit the possible roles for the
proxy of rs3761959 or rs11264798 maybe exist.
Although the three previous eQTL studies were all from the
Caucasians rather than from the Han Chinese population,
however, the LD analysis between the two populations displayed
a similar LD block harboring CD5L and all three significant SNPs
located in FCRL3 (rs11264798, rs3761959 and rs7528684) falling
in the same LD block (Figure S3). Interestingly, there were two LD
blocks and the five genes (FCRL1-5) were located in the first LD
block in the HapMap CEU populations (Figure S3A). Whilst,
among three LD blocks in CHB and JPT populations, two genes
(FCRL5-4) and three genes (FCRL3-1) were located in two different
LD blocks, respectively (Figure S3B).
FCRL3 gene is one of five FCRL genes that shares significant
structural homology to classical receptors for immunoglobulin
constant chains (Fc receptors) [35] and encodes a protein
containing an immunoreceptor-tyrosine activation motif and
immunoreceptor-tyrosine inhibitory motif in its cytoplasmic
domain [36]. FCRL3 is highly expressed in lymphoid organs,
particular strongly on the surface of the B-cells, but also on that of
the T-cells [16]. Among B-cell subsets, FCRL3 molecule is present
on mature, germinal center, memory, plasma cells, and bone
marrow immature B cells suggesting for its key role in the
development, maturation, and function of B-lymphocytes [37].
The pathogenic activation of FCRL3 expression is suggested to
lead to the down-regulation of B cell receptor-mediated signaling,
incomplete induction of anergy and deletion in autoreactive B-
cells, and, finally, to breakdown of B-cell tolerance [38]. Presence
of FCRL3 was also demonstrated on the surface of a subset of Treg
cells characterized by lower relative response to antigenic
stimulation and reduced suppressor activity [39]. In the original
report, rs7528684 was suggested to have functional significance as
the disease-associated C allele increased affinity for NF-KB
transcription factor and showed enhanced transcription rate in
luciferase assay [16]. In our study, CD19
+ B-cells had the highest
expression of FCRL3 among the four subsets of PBMCs and the
risk allele C of rs7528684 was significantly correlated with elevated
mRNA expression level of FCRL3 mainly in CD19
+ B cells and
CD8
+ T subsets, secondly in CD4
+ T subsets and CD14
+
monocytes. Moreover, our epigenetic analysis from ENCODE
database and TFSEARCH software analysis also manifested that
the risk allele C of rs7528684 could bind to NF-KB transcription
factor. Therefore, we proposed that FCRL3 gene and its proxy
SNP rs7528684 can be involved in the pathogenesis of GD by
excessive inhibiting B cell receptor signaling and the impairment
of suppressing function of Tregs.
In summary, our study provided the unequivocal evidence that
FCRL3 was the susceptibility gene of GD and its proxy SNP
rs7528684 may be the etiology variant to predispose to GD in
Chinese Han population.
Supporting Information
Figure S1 Regional plots of association results and
linkage disequilibrium structure of 58 SNPs. Panel A
shows the linkage disequilibrium (LD) structure for the 8 SNPs
with high LD with rs3761959 in the first LD block and 50 SNPs
that could not be improved in the model with rs3761959 in the
second LD block in the GWAS samples. Panel B shows the GD
association of 58 SNPs with P,2.30610
26the linkage disequilib-
rium (LD) structure for the 51 SNPs in the GWAS samples. The
color of each genotyped SNP spot reflects its r
2 with the top SNP
within each association locus shown as a large red diamond, and
smaller values changing from red to white. Genetic recombination
rates are shown in cyan. Genetic recombination rates, estimated
using the 1000 Genomes pilot 1 CHB and JPT samples, are
showing cyan. Physical positions are based on NCBI build 36.
(TIF)
Figure S2 The linkage disequilibrium structure of 210
SNPs including rs6679793 in the GWAS scan cohort. The
210 SNPs contains 209 SNPs correlated to the FCRL3 expression
and rs6679793 which is the top SNP correlated to the FCRL5
expression.
(TIF)
Figure S3 The linkage disequilibrium structure for the
region 155,744-156,152 Kb at 1q21.1 in the CEU (A) and
CHB and JPT (B) population from the HapMap phase II
24 release. Coloring in the figure is according to r
2.
(TIF)
Table S1 Association results of the imputed and typed
SNPs in 1q21.1 region with GD in initial genome-wide
scan.
(XLS)
Table S2 The comparison among the results from three
studies on FCRL genes in 1q21.1.
(XLS)
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